UBS Group upgraded shares of Alcentra Capital (NASDAQ:ABDC) from an underperform rating to a market perform rating in a research note released on Thursday, The Fly reports.

ABDC has been the topic of a number of other research reports. Rowe downgraded Alcentra Capital from an outperform rating to an underperform rating in a research note on Wednesday, November 8th. ValuEngine upgraded Alcentra Capital from a hold rating to a buy rating in a research note on Monday, October 2nd. Keefe, Bruyette & Woods restated a hold rating and set a $9.50 price target on shares of Alcentra Capital in a research note on Friday, November 10th. Finally, Raymond James Financial downgraded Alcentra Capital from an outperform rating to an underperform rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $12.83.

Alcentra Capital (NASDAQ ABDC) traded up $0.24 during trading hours on Thursday, reaching $8.88. The company had a trading volume of 222,287 shares, compared to its average volume of 111,311. The stock has a market cap of $126.50, a P/E ratio of -177.56 and a beta of 0.62. Alcentra Capital has a 12-month low of $7.00 and a 12-month high of $14.73.

Alcentra Capital (NASDAQ:ABDC) last released its quarterly earnings results on Monday, November 6th. The asset manager reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. The firm had revenue of $7.61 million for the quarter. Alcentra Capital had a positive return on equity of 11.32% and a negative net margin of 2.25%. research analysts expect that Alcentra Capital will post 1.29 EPS for the current fiscal year.

Alcentra Capital declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 6th that authorizes the company to repurchase $2.50 million in outstanding shares. This repurchase authorization authorizes the asset manager to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

The business also recently announced a quarterly dividend, which was paid on Thursday, January 4th. Shareholders of record on Friday, December 29th were paid a $0.25 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $1.00 annualized dividend and a dividend yield of 11.26%. Alcentra Capital’s dividend payout ratio (DPR) is currently -1,999.60%.

In other Alcentra Capital news, Director Paul J. Echausse sold 10,000 shares of Alcentra Capital stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $7.45, for a total value of $74,500.00. Following the transaction, the director now directly owns 58,946 shares in the company, valued at approximately $439,147.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven H. Reiff bought 6,900 shares of the stock in a transaction on Monday, November 13th. The stock was bought at an average price of $7.23 per share, for a total transaction of $49,887.00. Following the completion of the purchase, the director now directly owns 35,246 shares in the company, valued at approximately $254,828.58. The disclosure for this purchase can be found here. Insiders acquired a total of 11,730 shares of company stock worth $83,956 over the last quarter. Company insiders own 4.96% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Muzinich & Co. Inc. lifted its holdings in shares of Alcentra Capital by 34.7% in the 2nd quarter. Muzinich & Co. Inc. now owns 610,164 shares of the asset manager’s stock valued at $8,292,000 after buying an additional 157,251 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Alcentra Capital by 45.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 242,865 shares of the asset manager’s stock valued at $3,300,000 after buying an additional 76,115 shares during the period. Wasatch Advisors Inc. lifted its holdings in shares of Alcentra Capital by 82.9% in the 3rd quarter. Wasatch Advisors Inc. now owns 34,124 shares of the asset manager’s stock valued at $365,000 after buying an additional 15,469 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Alcentra Capital in the 2nd quarter valued at approximately $219,000. Finally, Carnegie Capital Asset Management LLC lifted its holdings in shares of Alcentra Capital by 8.1% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 20,011 shares of the asset manager’s stock valued at $232,000 after buying an additional 1,500 shares during the period. 32.06% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/alcentra-capital-abdc-lifted-to-market-perform-at-ubs-group/1807240.html.

Alcentra Capital Company Profile

Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.

The Fly

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.